While the research community has been focused on which peptides might get regulatory approval, a different kind of story has been playing out in the manufacturing world. On 20 July 2026, Samsung Biologics announced a $1.8 billion all-cash bid to acquire PolyPeptide Group, one of the world’s largest specialised peptide manufacturers.
This is South Korea’s largest biopharma acquisition to date, and it tells us something important about where the peptide industry is heading.
The Deal
Samsung Biologics, a contract development and manufacturing organisation (CDMO) based in Incheon, is offering 1.46 billion Swiss francs ($1.81 billion USD) for 100% of PolyPeptide Group. The offer represents a 40% premium to PolyPeptide’s share price in April 2026, when takeover speculation first started circulating.
The boards of both companies have approved the transaction. A tender offer will launch in August 2026, and if Samsung secures the required two-thirds majority ownership, they’ll delist PolyPeptide from the Swiss stock exchange. The deal is expected to close by the end of 2026.
Who is PolyPeptide?
PolyPeptide is a Swiss-headquartered peptide CDMO that operates manufacturing sites across Sweden, Belgium, France, the United States, and India, with a corporate office in Switzerland and an innovation centre in Strasbourg. The company reported revenues of €389 million in 2025, up more than 15% year-on-year.
What makes PolyPeptide particularly attractive is its positioning in the metabolic disease space. The company has said it’s modelling 25-30% revenue growth in 2026, and expects to double its annual turnover by 2028. That growth is being driven almost entirely by demand for GLP-1 and related peptide manufacturing.
“We have transformed PolyPeptide into one of the leading focused peptide CDMOs globally, with a rich pipeline, deep exposure to the fast-growing metabolics space, and a marked acceleration in sales growth and profitability,” said PolyPeptide CEO Juan Jose Gonzalez.
Why Samsung Wants In
Samsung Biologics is already a major player in biologic medicines - they work with 17 of the top 20 global pharmaceutical companies and generated approximately $3.5 billion in revenue in 2025. But their expertise has been in antibodies and antibody-drug conjugates (ADCs), not peptides.
This acquisition is Samsung’s entry ticket into the peptide manufacturing market, and it’s a big one. John Rim, Samsung Biologics CEO, was explicit about the strategy: “This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides, including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India.”
The GLP-1 market is the key driver. Global demand for GLP-1 receptor agonists - semaglutide, tirzepatide, and the next generation of compounds currently in trials - has outstripped manufacturing capacity. Novo Nordisk and Eli Lilly have both invested billions in expanding their own production facilities, but the demand for contract manufacturing continues to grow as more companies enter the space.
What This Means for the Peptide Supply Chain
The Samsung-PolyPeptide deal is part of a broader trend of consolidation in peptide manufacturing. The specialised capabilities required to produce peptides at scale - solid-phase synthesis, purification, quality control - are not trivial. There are relatively few companies worldwide that can do it at pharmaceutical grade, and the barriers to entry are high.
When a company like Samsung spends $1.8 billion to enter the market, it signals that the demand for peptide manufacturing is expected to grow significantly over the coming years. The C&EN reported that this deal reflects a broader industry belief that peptide production capacity will be a bottleneck for the next decade.
For the research community, the implications are mixed. On one hand, increased manufacturing capacity and competition could eventually lead to lower costs and better access. On the other hand, consolidation means fewer independent manufacturers, which could reduce options for smaller research organisations and compounding pharmacies.
The Bigger Picture
This acquisition sits alongside several other major deals in the obesity and metabolic disease space in 2026:
- Vertex Pharmaceuticals’ $10 billion acquisition of Crinetics Pharmaceuticals
- The $2.9 billion Soleno acquisition
- Pfizer’s continued investment in its obesity pipeline
The peptide and GLP-1 space is no longer a niche corner of pharmaceutical research. It’s become one of the most active areas of deal-making in the entire industry. Samsung’s entry into peptide manufacturing is a bet that this growth will continue for years.
For Australian researchers and the broader community, the key takeaway is that the infrastructure supporting peptide research and manufacturing is rapidly expanding. More manufacturing capacity means more supply, more competition, and eventually - potentially - better access to research-grade compounds.
Stay Connected
Join the Grey Highway Telegram community to discuss what this manufacturing consolidation means for research access in Australia.
For more on the compounds driving this manufacturing boom, see our pages on semaglutide, tirzepatide, and retatrutide.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.